

C.2.12. Sediment-Water Chironomid Life-Cycle Toxicity Test (OECD TG 233)

Status: Assay validated by the OECD.

452. Modality detected/endpoints: This long-term *in vivo* assay with the dipteran insect *Chironomus* spp. is responsive to juvenile hormone (JH) (ant)agonists and ecdysteroid (Ec) (ant)agonists which can interfere with such processes as metamorphosis, moulting, growth and reproduction. It exposes the test organisms over two generations. It is important to note, however, that none of the endpoints in this apical test are specifically responsive to JH- or Ec-active chemicals, and the assay will give positive results with many other substances. The lack of internationally validated mechanistic assays for endocrine activity in insects may prevent firm conclusions about whether test chemicals are endocrine disruptors (EDs) in this taxon, although *in vitro* assays for JH and Ec activity are available in the literature. However, the data from the test may nevertheless be of value for classification and hazard identification/characterisation.

Background to the assay

453. This life cycle assay can be run with one of several chironomid species, including *Chironomus riparius*, *C. dilutus* and *C. yoshimatsui*. It can also be operated in one of two formats, with the test chemical spiked either into the ambient water or into the sediment, thus allowing sparingly soluble or hydrophobic chemicals to be tested. The test with *C. riparius* and *C. yoshimatsui* takes 44 days, while with *C. dilutus* it continues for *ca.* 100 days. The exposure to a range of test concentrations begins with first instar larvae (F0) and continues to fully emerged adulthood of the second generation (F1), so two cycles of reproduction are evaluated.

454. The assay is relatively new (approved by the OECD in 2010), but the available data to date (e.g. Hahn, Liess and Schulz [2001]; Taenzler et al. [2007]; Jungmann et al. [2009]; Tassou and Schulz [2009, 2013]) show that chemicals acting as ant(agonists) of both the JH and Ec hormonal pathways can produce effects on most of the available endpoints.

When/why the assay may be used

455. Although OECD TG 233 could, in principle, be used at any stage in the hazard assessment process, the most likely use scenario will be when there are already some *in vitro* and *in vivo* data available about the possible JH or Ec activity and/or effects of a chemical. Given the significant degree of endocrine system conservation across the arthropods, effects in OECD TG 233 may also indicate the possibility of related activity in other arthropods such as crustaceans (cladocera, copepods and decapods).

456. It is not recommended that OECD TG 233 is deployed as a primary test for JH or Ec activity and effects, but it should be noted that there are no standardised *in vitro* screens for JH or Ec (ant)agonists, although some are described in the scientific literature (e.g. Cherbas, Koehler and Cherbas, 1989).

Existing data to be considered

457. Existing information on endocrine-related effects from other arthropods should also be considered before deployment of OECD TG 233, given the commonality of endocrine mechanisms in these taxa. Existing data available might also include one or more of a range of *in silico* or *in vitro* results which suggest that JH or Ec disruption may occur *in vivo* (but note the limitations of this approach, as indicated above). Such indicators of possible JH or Ec activity might include quantitative structure activity relationship (QSAR) predictions of JH/Ec activity, “read-across” from *in vivo* results obtained with structurally related chemicals or positive results from an *in vitro* screen for JH/Ec (ant)agonist activity. In addition, *in vivo* data should ideally be available from one or more of several assays, possibly including the Short-Term Juvenile Hormone Activity Screening Assay (SJHASA), the Sediment-Water Chironomid Toxicity Test Using Spiked Sediment or Water (OECD TG 218/219), or the *Daphnia magna* Reproduction Test with male neonate option (OECD TG 211). If positive data are available from the *Daphnia* Multigeneration Test (DMGT), these should also be taken into account.

458. In order to provide information relevant for assessing whether or not a chemical may fulfil the WHO/IPCS (2002) definition of an ED, the study design has to be sufficiently robust to demonstrate the presence or absence of effects. In the dose selection, the investigator should also consider and ensure that data generated are adequate to fulfil the regulatory requirement across OECD countries as appropriate (e.g. hazard and risk assessment and labelling, ED assessment, etc.). The top dose or concentration should be sufficiently high to give clear systemic (i.e. non endocrine-specific) toxicity in order to ensure that a wide range of exposures (high to low) is tested. However, endocrine effects observed solely in the presence of clear systemic toxicity should be interpreted with caution and may be disregarded when sufficiently justified to be caused by secondary effects which are unlikely to be due to endocrine activity. The reason for this advice is a concern that some endocrine active substance (EAS) sensitive assays are being run at doses/concentrations of EASs that are too low to trigger direct impacts on the endocrine system. This guidance document is not the place to address this issue directly, but it should be considered when EAS-sensitive test guidelines (TGs) are revised in the future. In addition, the number and spacing of dose/concentration levels should also be adequate to fulfil the objectives of the study (e.g. to demonstrate dose response relationships if this is required).

Scenarios: Positive and negative results combined with existing data

459. The scenarios (A to R) presented in [Table C.2.12](#) represent all the possibilities of positive or negative results in combination with the presence or absence of existing data. The action taken will also depend on the regulatory environment, but the considerations given here are generally science based. Wherever possible, the recommended “next step which could be taken” avoids unnecessary animal testing. However, sometimes conducting an animal test will be indicated and then the relevance of species, strain and exposure route should always be considered. Further considerations specific to each scenario are given in the table.

460. Positive results obtained with OECD TG 233 (Table C.2.12, Scenarios A-I) result in the conclusion that the test chemical has adverse apical effects, at least in insects, but these are not necessarily caused by JH or Ec activity. However, although a positive response of the OECD TG 233 indicates that the chemical has adverse effects in insects, it

should be noted that crustacean species such as *Daphnia* have a parthenogenetic reproductive strategy and so may respond differently to *Chironomus*. Therefore, if countries need further evidence concerning growth and sexual development, etc. in this phylum, a Harpacticoid Copepod Development and Reproduction Test (OECD GD 201) and/or the DMGT would be able to provide information on adverse effects in other arthropod species. In other words, in order to strengthen weight of evidence, a positive result in OECD TG 233 could be followed by GD 201 (Level 4) and/or the DMGT (Level 5). Existing data suggesting endocrine-specific activity (e.g. positive *in vitro* data, or positive *in vivo* data from other species) will strengthen the case for additional testing still further.

461. The situation in which OECD TG 233 gives a negative result (Table C.2.12, Scenarios J-R) needs careful consideration of any existing data. If these data suggest that the chemical is endocrine active both *in vitro* and *in vivo* (Scenario J), then it is possible that OECD TG 233 is simply insufficiently sensitive.

462. If OECD TG 233 and existing *in vivo* data are all negative, but *in vitro* data reveal some JH or Ec activity (Scenario K), the probability is that the test chemical is not sufficiently potent to produce JH/Ec (ant)agonism *in vivo* in arthropods, or it may be rapidly metabolised. In such a situation, further testing is probably not necessary.

463. On the other hand, if OECD TG 233 and the *in vitro* tests are negative (Scenario M), but there are positive existing *in vivo* data, the nature of those existing data should be considered. Unless the existing data are from another insect, the chemical is possibly not a JH or Ec (ant)agonist acting in insects, but it may be more potent in species (e.g. crustaceans) or life stages that have not been tested. In this situation, the existing *in vivo* data should be used to guide decisions about whether to conduct any further testing (e.g. with OECD GD 201).

464. Finally, a negative OECD TG 233, set against a background of negative *in vitro* and *in vivo* data (Scenario N), suggests that the test chemical is probably not a JH or Ec (ant)agonist *in vitro* or *in vivo*, and further action is unnecessary.

465. In each of the above scenarios, it is possible that existing data will be equivocal, or there may be no existing data. This will weaken the conclusions which can be drawn about a negative OECD TG 233, and this is reflected in [Table C.2.12](#). However, a lack of mechanistic data on JH or Ec activity should ideally be addressed before any further *in vivo* testing is finally conducted, although as indicated above, *in vitro* JH/Ec screens have not yet been internationally standardised. On the other hand, if OECD TG 233 is positive, further *in vivo* testing would generally be needed to quantify any adverse effects in crustaceans, even if all existing data are equivocal, or if there are no existing data. Again, however, it may be useful to obtain some mechanistic information before conducting further *in vivo* testing. There is also the possibility that equivocal mechanistic data may be the result of multiple modes of endocrine action. Under some circumstances, two opposite modes of simultaneous action (e.g. JH or Ec agonistic and antagonistic) could, depending on dose, lead to a minimisation or abolition of adverse effects, while in others two different modes of action (MOA) could potentially reinforce effects on the OECD TG 233 endpoint. If multiple MOA are suspected, either from the existing results or based on QSAR/read-across/integrated approaches, this situation should be investigated further if needed for regulatory decision making.

466. The scenario in which the results of OECD TG 233 are themselves equivocal has not been dealt with in Table C.2.12, for reasons of brevity. In this context, an equivocal result might be an inconsistent concentration-response (e.g. no effect at a high concentration but effects at a lower concentration), or a result which borders on statistical significance.

Without knowing the exact circumstances, reliable advice cannot be given, but the opinions of an experienced ecotoxicologist should be sought. Clearly, however, such equivocal results do not necessarily rule out the existence of *in vivo* endocrine activity. If possible reasons for false negatives are suspected, OECD TG 233 could be repeated (e.g. conduct it at lower concentrations which avoid systemic toxicity).

467. In summary, positive results in OECD TG 233 indicate that a chemical has adverse effects in insects which may or may not be via JH or Ec (ant)agonism. This may need to be followed up with further apical testing with crustaceans. Negative results in OECD TG 233 do not necessarily mean that the chemical is not a potential ED – a judgement about the endocrine disruption potential in other arthropods will have to be made based on a weight of evidence evaluation of existing *in vitro* and *in vivo* data.

References

- Cherbas, L., M.M.D. Koehler and P. Cherbas (1989), “Effects of juvenile hormone on the ecdysone response of *Drosophila* Kc cells”, *Developmental Genetics*, Vol. 10/3, pp. 177-188, <https://doi.org/10.1002/dvg.1020100307>.
- Hahn, T., M. Liess and R. Schulz (2001), “Effects of the hormone mimetic insecticide tebufenozide in *Chironomus riparius* larvae in two different exposure setups”, *Ecotoxicology and Environmental Safety*, Vol. 49/2, pp. 171-178, <https://doi.org/10.1006/eesa.2001.2055>.
- Jungmann, D. et al. (2009), “Chronic toxicity of fenoxycarb to the midge *Chironomus riparius* after exposure in sediments of different composition”, *Journal of Soils and Sediments*, Vol. 9/2, pp. 94-102, <http://dx.doi.org/10.1007/s11368-009-0056-2>.
- Taenzler, V. et al. (2007), “Chironomids: Suitable test organisms for risk assessment investigations on the potential endocrine disrupting properties of pesticides”, *Ecotoxicology*, Vol. 16/1, pp. 221-230, <https://doi.org/10.1007/s10646-006-0117-x>.
- Tassou, K.T. and R. Schulz (2013), “Low field-relevant tebufenozide concentrations affect reproduction in *Chironomus riparius* (Diptera: Chironomidae) in a long-term toxicity test”, *Environmental Science and Pollution Research*, Vol. 20/6, pp. 3735-3742, <http://dx.doi.org/10.1007/s11356-012-1311-4>.
- Tassou, K.T. and R. Schulz (2009), “Effects of the insect growth regulator pyriproxyfen in a two-generation test with *Chironomus riparius*”, *Ecotoxicology and Environmental Safety*, Vol. 72, pp. 1058-1062, <https://doi.org/10.1016/j.ecoenv.2009.02.001>.
- WHO/IPCS (2002), “Global assessment of the state-of-the-science of endocrine disrupters”, Damstra, T. et al. (eds.) WHO/PCS/EDC/02.2, World Health Organization, Geneva, www.who.int/ipcs/publications/new_issues/endocrine_disruptors/en.

**Table C.2.12. Sediment-Water Chironomid Life-Cycle Toxicity Test (OECD TG 233):
Guidance for scenarios of combinations of results with existing data**

This table represents possible conclusions to be drawn from assay data, and a next step which could be taken if further evidence is required about possible endocrine disrupting properties and/or effects. The guidance offered is not meant to be prescriptive, but provides science-based considerations. It encourages the use of all available data and expert judgement in a weight of evidence approach. Regional and national interpretation of results and “next steps” may vary.

The conclusions are grouped into a series of scenarios (A-R), each scenario representing a different combination of assay results, existing *in vitro* data and existing *in vivo* data. The symbol “+” indicates that the data in question represent a positive result, <-” indicates a negative result, and “Eq/0” indicates that the data are either equivocal or are not available.

Existing results: * “Mechanism (*in vitro* mechanistic data)” assumes that mechanistic data are available from available from juvenile hormone- (JH) or ecdysteroid (Ec-) based assays. JH or Ec assays concerning mechanisms of disruption may be available, but they are have not yet been internationally standardised. In practice, data from all assays may not be available and therefore this must be taken into account when deciding on the “next step”.


Existing results: ** “Effects (*in vivo* effects of concern)” assumes effects have been observed in other *in vivo* screens/tests which give rise to concern that the test chemical may be a JH or Ec disrupter.

Scenarios	Result of OECD TG 233	Existing results		Possible conclusions	Next step which could be taken to strengthen weight of evidence if necessary	Other considerations
		Mechanism (<i>in vitro</i> mechanistic data)*	Effects (<i>in vivo</i> effects of concern)**			
A	+	+	+	Strong evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by juvenile hormone (JH) or ecdysteroid (Ec) (ant)agonists, plus possible JH or Ec effects in other arthropods.	It would be desirable (if not already conducted) to perform an apical test with crustaceans (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; and/or the <i>Daphnia</i> Multigeneration Test [DMGT]).	Based on the limited scope of current <i>in vitro</i> screens, the positive <i>in vitro</i> data suggest that the test chemical is a JH or Ec (ant)agonist. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> .
B	+	+	–	Strong evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by JH or Ec (ant)agonists.	It would be desirable (if not already conducted) to perform an apical test with crustaceans (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; and/or the DMGT).	Based on the limited scope of current <i>in vitro</i> screens, the positive <i>in vitro</i> data suggest that the test chemical is a JH or Ec (ant)agonist. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> .
C	+	+	Eq/0	Strong evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by JH or Ec (ant)agonists.	It would be desirable (if not already conducted) to perform an apical test with crustaceans (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; and/or the DMGT).	Based on the limited scope of current <i>in vitro</i> screens, the positive <i>in vitro</i> data suggest that the test chemical is a JH or Ec (ant)agonist. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> . It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple modes of action (MOA). If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.
D	+	–	+	Strong evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by JH or Ec (ant)agonists, plus possible JH or Ec effects in other arthropods.	It would be desirable (if not already conducted) to perform an apical test with crustaceans (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; and/or the DMGT).	The lack of <i>in vitro</i> JH or Ec activity is not necessarily evidence against any JH/Ec activity, due to the limited nature of current <i>in vitro</i> JH and Ec screens. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> .
E	+	–	–	Some evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by JH or Ec (ant)agonists.	It would be desirable (if not already conducted) to perform an apical test with crustaceans (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; and/or the DMGT).	The lack of <i>in vitro</i> JH or Ec activity is not evidence against any JH/Ec activity, due to the limited nature of current <i>in vitro</i> JH and Ec screens. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> .

Scenarios	Result of OECD TG 233	Existing results		Possible conclusions	Next step which could be taken to strengthen weight of evidence if necessary	Other considerations
		Mechanism (<i>in vitro</i> mechanistic data)*	Effects (<i>in vivo</i> effects of concern)**			
F	+	–	Eq/0	Some evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by JH or Ec (ant)agonists.	Given the absence or equivocal nature of existing <i>in vivo</i> data, it might also be sensible to conduct a JH/Ec-responsive crustacean assay (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201) or a JH-responsive DMGT.	The lack of <i>in vitro</i> JH/Ec activity is not evidence against any JH/Ec activity, due to the limited nature of current <i>in vitro</i> JH/Ec screens. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> . It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.
G	+	Eq/0	+	Strong evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by JH or Ec (ant)agonists, plus possible JH or Ec effects in other arthropods.	Given the absence or equivocal nature of existing <i>in vitro</i> data, it would be desirable to obtain further <i>in vitro</i> data on JH/Ec activity if possible. It might also be sensible to conduct a JH/Ec-responsive crustacean assay (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201) or a JH-responsive DMGT.	If a new <i>in vitro</i> mechanistic assay is conducted, note that a negative does not mean that the test material has no JH/Ec activity. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> . It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.
H	+	Eq/0	–	Some evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by JH or Ec (ant)agonists.	Given the absence or equivocal nature of the <i>in vitro</i> mechanistic data, it might also be helpful to conduct an <i>in vitro</i> screen for JH/Ec activity. It might also be sensible to conduct a JH/Ec-responsive crustacean assay (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201) or a JH-responsive DMGT.	If a new <i>in vitro</i> mechanistic assay is conducted, note that a negative does not mean that the test material has no JH/Ec activity. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> . It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.

Scenarios	Result of OECD TG 233	Existing results		Possible conclusions	Next step which could be taken to strengthen weight of evidence if necessary	Other considerations
		Mechanism (<i>in vitro</i> mechanistic data)*	Effects (<i>in vivo</i> effects of concern)**			
I	+	Eq/0	Eq/0	Some evidence for adverse <i>in vivo</i> effects in insects, possibly but not necessarily caused by JH or Ec (ant)agonists.	Given the absence or equivocal nature of the <i>in vitro</i> mechanistic data, it might also be helpful to conduct an <i>in vitro</i> screen for JH/Ec activity. It might also be sensible to conduct a JH/Ec-responsive crustacean assay (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201) or a JH-responsive DMGT.	If a new <i>in vitro</i> mechanistic assay is conducted, note that a negative does not mean that the test material has no JH/Ec activity. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> . It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.
J	–	+	+	The test chemical is probably a JH or Ec (ant)agonist without adverse effects in insects, although it is possible that <i>Chironomus</i> spp. respond atypically in this case.	Some regulatory authorities may conclude that no further evidence is required. However, it might be desirable to obtain data from crustaceans (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; or the DMGT) if these are not already available.	Based on the limited scope of current <i>in vitro</i> screens, the positive <i>in vitro</i> data suggest that the test chemical is a JH/Ec (ant)agonist. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> .
K	–	+	–	The test chemical is probably a JH or Ec (ant)agonist without adverse effects in insects or other taxa, although it is possible that <i>Chironomus</i> responds atypically in this case.	If there is no activity in crustaceans or insects, further evidence is probably not needed.	Based on the limited scope of current <i>in vitro</i> screens, the positive <i>in vitro</i> data suggest that the test chemical is a JH/Ec (ant)agonist.
L	–	+	Eq/0	The test chemical is probably a JH or Ec (ant)agonist without adverse effects in insects, although it is possible that <i>Chironomus</i> responds atypically in this case.	Some regulatory authorities may conclude that no further evidence is required, but if crustacean data are absent, it might be desirable to conduct a Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; or a DMGT.	Based on the limited scope of current <i>in vitro</i> screens, the positive <i>in vitro</i> data suggest that the test chemical is a JH/Ec agonist. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> . It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.
M	–	–	+	The test chemical is probably without JH or Ec activity in insects, although it is possible that <i>Chironomus</i> responds atypically in this case.	Some regulatory authorities may conclude that no further evidence is required. However, it might be desirable to obtain data from crustaceans (e.g. Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; or a DMGT) if these are not already available.	The lack of <i>in vitro</i> JH/Ec activity is not evidence against any JH activity, due to the limited nature of current <i>in vitro</i> JH screens. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> .

Scenarios	Result of OECD TG 233	Existing results		Possible conclusions	Next step which could be taken to strengthen weight of evidence if necessary	Other considerations
		Mechanism (in vitro mechanistic data)*	Effects (in vivo effects of concern)**			
N	–	–	–	The test chemical is probably without JH or Ec activity in arthropods.	No further action is necessary.	–
O	–	–	Eq/0	The test chemical is probably without JH or Ec activity in arthropods.	Some regulatory authorities may conclude that no further evidence is required. However, it might be desirable to obtain data from crustaceans (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; or a DMGT) if these are not already available.	The lack of <i>in vitro</i> JH/Ec activity is not evidence against any JH activity, due to the limited nature of current <i>in vitro</i> JH screens. It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> . It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.
P	–	Eq/0	+	The test chemical is probably without JH or Ec activity in insects, although it is possible that <i>Chironomus</i> responds atypically in this case.	Some regulatory authorities may conclude that no further evidence is required. Also, if clear <i>in vitro</i> mechanistic data are missing, it might be desirable to obtain some.	If a new <i>in vitro</i> mechanistic assay is conducted, note that a negative does not mean that the test material has no JH/Ec activity. It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.
Q	–	Eq/0	–	The test chemical is probably without JH or Ec activity in arthropods.	No further action is necessary.	It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.
R	–	Eq/0	Eq/0	The test chemical is probably without JH or Ec activity in insects and possibly crustaceans.	Some regulatory authorities may conclude that no further evidence is required. However, it might be desirable to obtain data from crustaceans (e.g. the Harpacticoid Copepod Development and Reproduction Test – OECD GD 201; or a DMGT) if these are not already available.	It should be noted that chironomids reproduce sexually and therefore may respond differently to a parthenogenetic species such as <i>Daphnia</i> . It should be borne in mind that equivocal data may be due to a variety of causes, including experimental error, very weak endocrine activity or multiple MOA. If the latter case is suspected, it may be necessary to investigate the matter further and/or increase the weight given to the mechanistic information.



From:
Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption

Access the complete publication at:
<https://doi.org/10.1787/9789264304741-en>

Please cite this chapter as:

OECD (2018), "Sediment-Water Chironomid Life-Cycle Toxicity Test (OECD TG 233)", in *Revised Guidance Document 150 on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption*, OECD Publishing, Paris.

DOI: <https://doi.org/10.1787/9789264304741-17-en>

This work is published under the responsibility of the Secretary-General of the OECD. The opinions expressed and arguments employed herein do not necessarily reflect the official views of OECD member countries.

This document and any map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area.

You can copy, download or print OECD content for your own use, and you can include excerpts from OECD publications, databases and multimedia products in your own documents, presentations, blogs, websites and teaching materials, provided that suitable acknowledgment of OECD as source and copyright owner is given. All requests for public or commercial use and translation rights should be submitted to rights@oecd.org. Requests for permission to photocopy portions of this material for public or commercial use shall be addressed directly to the Copyright Clearance Center (CCC) at info@copyright.com or the Centre français d'exploitation du droit de copie (CFC) at contact@cfcopies.com.